Medical Affairs (MA) organizations within biopharma companies face great opportunity and great challenges. More than ever, MA is being viewed as a critical strategic hub for the entire pharmaceutical enterprise. However, MA has more demands being placed upon it that ever before. We conducted 24 one-on-one interviews with MA senior leaders (C-suite, SVPs, VPs, and select Senior Directors) from 16 biopharma companies. The participating companies included eight large organizations and eight emerging or mid-size firms. The conversations addressed these leaders’
assessment of MA’s current situation and the steps needed for MA functions to become “Best Practice Organizations” so that they can take full advantage of the current opportunity and deliver maximum value to patients and their companies.
